A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
To study the effect of pars plana vitrectomy on the intravitreal pharmacokinetics of
ranibizumab and to compare the half-life of ranibizumab and aflibercept.